DT03 Rec'd PCT/PTO 26 JUL 2004

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 457 868 562 4 S Express Mail Label Number July 26, 2004

Form PTO-1390-MOD U. S. (REV 10-96)	Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER ON/4-32331A						
TRANSMITTAL LETTER TO 1	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)							
DESIGNATED/ELECTED O CONCERNING A FILING UN	10/502533							
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
PCT/EP03/00803	27 January 2003 (27.01.03)	28 January 2002 (28.01.02)						
TITLE OF INVENTION								
BETA - HOMOLYSINE CONJUGATES AND THEIR USE AS TRANSPORT ENHANCER								
APPLICANT(S) FOR DO/EO/US								
CARLOS GARCIA-ECHEVERRIA								

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. 2. 3.		This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4.	\boxtimes	A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5.	⊠	A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. is transmitted herewith (required only if not transmitted by the International Bureau). b. has been transmitted by the International Bureau. (See Form PCT/IB/308)
6. 7.	☒	c. is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). a. are transmitted herewith (required only if not transmitted by the International Bureau). b. have been transmitted by the International Bureau.
8. 9. 10.		c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
Iten	ns 1	I. to 16. below concern document(s) or information included.
11.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13.	\square	A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.
14.		A substitute specification.
15.		A change of power of attorney and/or address letter.
16.	\boxtimes	Other items or information: Unexecuted Declaration and Application Data Sheet

TT12 Rec'd PCT/PTO 2 6 JUL 2004

U.S. APPLICATION NO. PCT/EP03/00803 ON/4-3233			B1A						
17. The following fees are submitted:			CALCULATION	S PTO USE ONLY					
BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):									
Search Report has been prepared by the EPO or JPO									
International preliminary examination fee paid to USPTO (37 CFF									
No international preliminary examination fee paid to USPTO (37 (but international search fee paid to USPTO (37 CFR 1.445(a)(2)).									
Neither international preliminary examination fee (37 CFR 1.482) international search fee (37 CFR 1.445(a)(2)) paid to USPTO									
International preliminary examination fee paid to USPTO (37 CFF and all claims satisfied provisions of PCT Article 33(2)-(4)									
ENTER APPROPRIATE BA	\$ 920								
Surcharge of \$130 for furnishing the oath of declaration later than 2 months from the earliest claimed priority date (37 CFR 1.492(e)).	\$								
CLAIMS NUMBER FILED NUMBER EXTRA									
Total claims 16 - 20 = 0	X \$	18	\$						
Independent claims 2 -3 = 0	X \$	· 86	\$						
MULTIPLE DEPENDENT CLAIM(S) (if applicable)	+ \$	290	\$ 000						
TOTAL OF ABO			\$ 920						
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be									
filed (Note 37 CFR 1.9, 1.27, 1.28).	\$ \$ 920								
D	OTAL =	J 320							
Processing fee of \$130 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)).									
TC	\$ 920								
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment (37 CFR 3.28, 3.31). \$40 per property	ompanied +	\$	-						
TOTAL	\$ 920								
			Amount to be:	\$					
			refunded charged	•					
a	o fees is england		Sharged	*					
	a. ☐ A check in the amount of \$ to cover the above fees is enclosed. b. ☒ Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$920 to cover the above fees. A								
duplicate copy of this form is enclosed.									
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.									
Send all correspondence to the address associated with Customer No. 001095, which is currently: Themse Havis									
Thomas Hoxie Novartis Corporate Intellectual Property One Health Plaza, Building 430 East Hanover, NJ 07936-1080 Lydia T. McNally Attorney for Applicant Reg. No. 36,214 (862) 778-7898									